Back to top
more

Fate Therapeutics (FATE)

(Delayed Data from NSDQ)

$2.42 USD

2.42
1,957,758

-0.13 (-5.10%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $2.42 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 8.47% and 3.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales

Incyte reports mixed third-quarter results as earnings miss estimates while revenues beat the same due to increased sales of Jakafi and Opzelura.

Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down

ALKS reports weaker-than-expected third-quarter 2024 results. Net sales of proprietary products increase year over year. Shares down.

VKTX Beats on Q3 Earnings, Stock Up on Obesity Pipeline Advancements

Viking Therapeutics' third-quarter earnings outpace estimates. The company plans to start a mid-stage study on its obesity pill before 2024-end.

EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down

Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus resources on in vivo pipeline development.

NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients

A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients compared to placebo.

Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy

Fate Therapeutics (FATE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow

FATE reports a lower-than-expected loss on higher revenues and lower operating expenses in the second quarter of 2024.

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 29.79% and 361.94%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Eyenovia, Inc. (EYEN) Reports Q2 Loss, Misses Revenue Estimates

Eyenovia (EYEN) delivered earnings and revenue surprises of -5.88% and 98.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates

Werewolf Therapeutics (HOWL) delivered earnings and revenue surprises of -13.16% and 42.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Break-Even Earnings for Q2

ChromaDex (CDXC) delivered earnings and revenue surprises of 100% and 1.35%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q2 Earnings and Revenue Estimates

Harmony Biosciences (HRMY) delivered earnings and revenue surprises of 600% and 0.73%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 0% and 140.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.

Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.

Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know

Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) posts Q1 results.

Ekta Bagri headshot

Novartis (NVS) to Report Q1 Earnings: What to Expect?

Novartis (NVS) key drugs Entresto, Kisqali and Pluvicto are likely to have fueled its top and bottom-line numbers in the first quarter.

What's in Store for Biogen (BIIB) This Earnings Season?

Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate.

J&J (JNJ) to Begin Pharma Q1 Earnings Season: What's in Store?

J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.

Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress

Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.

Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Myriad (MYGN) Down 1% Since Last Earnings Report?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.